Entropy Neurodynamics Webinar: Landmark results in treatment-resistant Binge Eating Disorder

Entropy Neurodynamics presents clinical findings from a Phase 2 trial of TRP-8803, an intravenously infused psilocybin treatment targeting treatment-resistant Binge Eating Disorder. The trial demonstrates efficacy in patient outcomes, specifically noting a 50 percent clinical remission rate and a meaningful 74 percent reduction in binge eating episodes. TRP-8803 is positiond as a precision-controlled, rapid-acting alternative to oral psilocybin, providing predictable dosing and the ability to reverse the drug effects during a session if necessary. The company emphasizes a strategy of developing scalable, pharmaceutical-grade therapies with strong intellectual property and biomarker tracking to address high-unmet needs in neuropsychiatric conditions like fibromyalgia and irritable bowel syndrome alongside Binge Eating Disorder.